PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ensartinib→

Ensartinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1370651-20-9
Molecular formula
C26H27Cl2FN6O3
Molecular weight
561.44 g/mol
Drug class
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Inhibits ALK kinase activity and downstream signalling in ALK-rearranged tumour cells; it also inhibits additional kinases including MET and ROS1 at pharmacologically relevant concentrations.
Indications / reported uses
  • Treatment of adults with ALK-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, as detected by an FDA-approved test under the US ENSACOVE indication

Sources: US FDA — Ensartinib approval, 18 December 2024 · US FDA prescribing information — ENSACOVE · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ensartinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ensartinib Permitted Daily Exposure (PDE) report (the Ensartinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ensartinib Occupational Exposure Limit (OEL) report (the Ensartinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.